Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Food Chem ; 441: 138329, 2024 May 30.
Article in English | MEDLINE | ID: mdl-38218146

ABSTRACT

This study is focused on exploring the effect of twin-screw high-moisture extrusion technology on the physico-chemical properties of ß-glucan-soybean protein isolate (SPI-BG) extrudates. Different proportions (0 %, 1 %, 2 %, 3 %, 4 %, 5 %) of oat ß-glucan (BG) were added with soybean protein isolate (SPI) to prepare SPI-BG extrudates. Results showed that the addition of a high quantity of ß-glucan (BG) decreased the elastic properties of soy protein isolate (SPI) extrudates and then increased. The strengthening of S1-S2-S3 interactions (hydrogen bonds, hydrophobic interactions, and disulfide bonds) was primarily responsible for this trend. Fourier transform infrared (FTIR) spectral analysis was conducted which revealed that BG did not significant affect random coil content of SPI. However, it was observed that α-helix content was increased significantly and the ß-sheet content was decreased. An observation was noted in the value of enthalpy (ΔH) change that increased from 115.80 J/g to 159.68 J/g.


Subject(s)
Soybean Proteins , beta-Glucans , Soybean Proteins/chemistry , Hydrophobic and Hydrophilic Interactions , Hydrogen Bonding
2.
Future Oncol ; 19(20): 1439-1450, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37497628

ABSTRACT

Purpose: To analyze whether adding PI3K/AKT/mTOR inhibitors to fulvestrant could restore endocrine therapy sensitivity for the treatment of postmenopausal patients with HR+, HER2- breast cancer. Methods: This meta-analysis was performed using RevMan 5.4 analysis software. Results: Nine studies that included a total of 3199 patients were analyzed. Compared with fulvestrant alone, the addition of PI3K/AKT/mTOR inhibitors significantly prolonged progression-free survival, overall survival and objective response rate of patients in both the total and PI3K-pathway-activated population. The number of grade 3-5 adverse events was also significantly higher. Conclusion: The addition of PI3K/AKT/mTOR to fulvestrant resulted in potential benefits; however, there may be a higher risk, which needs to be carefully managed.


Subject(s)
Breast Neoplasms , Humans , Female , Fulvestrant/therapeutic use , MTOR Inhibitors , Phosphatidylinositol 3-Kinases , Proto-Oncogene Proteins c-akt , Receptor, ErbB-2 , Antineoplastic Combined Chemotherapy Protocols/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL